At ArgusEye, we are dedicated to revolutionizing biopharmaceutical processing by offering sensors that allow real-time monitoring of critical process parameters. Our aim with the development of the Auga™ platform is to transform how the biopharma industry develops and manufactures biological drugs. We do this by providing cutting-edge technology for in-line and on-line monitoring, where we aim to reduce the need for time-consuming off-line analyses, and instead deliver rapid and accurate quality data within seconds. This will lead to quicker and more efficient process development, and ultimately production, addressing the increasing demand for new and effective biological drugs.

Our Vision

ArgusEye’s long-term goal is to establish Auga™ as the leading technology for in-line monitoring in the biopharma industry. Our aim is to incorporate our unique nanoplasmonic sensor system into existing production equipment, facilitating a seamless shift from traditional analysis methods to modern, real-time solutions. Using fiber optics and nanoplasmonic detection, we have designed a versatile system that can be customized for a wide range of biomolecular analyses, enabling companies to monitor quality attributes during both upstream and downstream processes.

Initial Applications of Auga™ 

The initial uses of Auga™ showcase the potential of our technology, with our primary focus on mAbs.The applications are endless, however, some of the first ones are:

  • Measurement of product breakthrough during column chromatography 

By monitoring product advancements in real-time, we can ensure optimal separation and purification of biological molecules, enhancing product quality and significantly reducing production costs.

  • Measurement of product titer 

Our technology allows for precise measurement of the concentration of biological products during the manufacturing process. This ensures that production occurs within specifications and that the final product meets the highest quality standards.

  • Monitoring of product variants and detection of known contaminants

With Auga™, we can detect and monitor product variants, including aggregates and the presence of unwanted components in real-time. This is crucial for ensuring drug purity and efficacy, enabling rapid corrections and minimizing the risk of production errors and batch deviations.

By developing Auga™, we aim to enhance the biopharma industry’s ability to develop and produce new biological drugs more quickly, efficiently, and cost-effectively. Our nanoplasmonic sensor system offers a robust and flexible solution for real-time monitoring of biomolecular interactions, which is essential to meet the current and future demands in drug development and production. With Auga™, we are taking a step toward a more integrated and advanced production environment, where quality and efficiency are paramount.